Cite
HARVARD Citation
Kaul, M. et al. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and translational science. 14 (5), pp. 1756-1768. [Online].